Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

13.23USD
16 Nov 2018
Change (% chg)

$-0.04 (-0.30%)
Prev Close
$13.27
Open
$13.14
Day's High
$13.45
Day's Low
$12.88
Volume
297,201
Avg. Vol
226,396
52-wk High
$32.15
52-wk Low
$11.83

Latest Key Developments (Source: Significant Developments)

Momenta Pharmaceuticals Q3 Loss Per Share $0.65
Wednesday, 7 Nov 2018 06:00am EST 

Nov 7 (Reuters) - Momenta Pharmaceuticals Inc ::MOMENTA PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 REVENUE $14.9 MILLION VERSUS I/B/E/S VIEW $17 MILLION.Q3 LOSS PER SHARE $0.65.Q3 EARNINGS PER SHARE VIEW $-0.57 -- THOMSON REUTERS I/B/E/S.MOMENTA IS PROVIDING UPDATED NON-GAAP OPERATING EXPENSE GUIDANCE OF APPROXIMATELY $230 - $240 MILLION FOR 2018.MOMENTA - $1.4 MILLION IN ADDITIONAL CHARGES RELATED TO RESTRUCTURING ARE ANTICIPATED TO BE RECORDED IN QUARTER ENDING DECEMBER 31, 2018..ESTIMATES THAT COLLABORATIVE REIMBURSEMENT REVENUES WILL BE APPROXIMATELY $0 - $2 MILLION IN Q4 OF 2018.  Full Article

Momenta Pharmaceuticals Announces Global Settlement With Abbvie
Tuesday, 6 Nov 2018 04:45pm EST 

Nov 6 (Reuters) - Momenta Pharmaceuticals Inc ::MOMENTA PHARMACEUTICALS ANNOUNCES GLOBAL SETTLEMENT WITH ABBVIE TO ENABLE COMMERCIALIZATION OF M923, A PROPOSED BIOSIMILAR TO HUMIRA® (ADALIMUMAB).MOMENTA PHARMACEUTICALS - PLANS TO SUBMIT BIOLOGICS LICENSE APPLICATION FOR M923 TO FDA IN Q4.MOMENTA PHARMACEUTICALS - PLANS TO SUBMIT MARKETING AUTHORIZATION APPLICATION IN EU IN H1 2019.  Full Article

Momenta Pharmaceuticals Reports Q4 Earnings Per Share $0.18
Wednesday, 21 Feb 2018 08:00am EST 

Feb 21 (Reuters) - Momenta Pharmaceuticals Inc ::MOMENTA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 REVENUE $64.6 MILLION VERSUS $34.2 MILLION.Q4 EARNINGS PER SHARE $0.18.‍NET INCOME IN 2017 PERIOD WAS DRIVEN BY RECOGNITION OF $50.0 MILLION UPFRONT PAYMENT FROM CSL AS REVENUE​.Q4 EARNINGS PER SHARE VIEW $-0.31, REVENUE VIEW $66.6 MILLION -- THOMSON REUTERS I/B/E/S.MOMENTA PHARMACEUTICALS - SEES ‍NON-GAAP OPERATING EXPENSE OF ABOUT $180 MILLION - $220 MILLION FOR 2018 AND $45 MILLION - $55 MILLION FOR Q1 2018​.  Full Article

Momenta Pharmaceuticals Announces FDA Approval And Launch Of Glatopa
Tuesday, 13 Feb 2018 01:15am EST 

Feb 13 (Reuters) - Momenta Pharmaceuticals Inc ::MOMENTA PHARMACEUTICALS ANNOUNCES FDA APPROVAL AND LAUNCH OF GLATOPA® (GLATIRAMER ACETATE INJECTION) 40 MG/ML.MOMENTA PHARMACEUTICALS- U.S. FDA HAS APPROVED SANDOZ'S ABBREVIATED NEW DRUG APPLICATION FOR GLATOPA (GLATIRAMER ACETATE INJECTION) 40 MG/ML​.MOMENTA PHARMACEUTICALS - SANDOZ INITIATED LAUNCH OF THE PRODUCT IN U.S..MOMENTA PHARMACEUTICALS - GLATOPA WAS DEVELOPED UNDER A COLLABORATION AGREEMENT BETWEEN MOMENTA AND SANDOZ AND IS PRODUCED IN THE US.  Full Article

Momenta Pharmaceuticals Planning For Glatopa 40 Mg Launch In 2H 2018 However
Monday, 8 Jan 2018 08:24am EST 

Jan 8 (Reuters) - Momenta Pharmaceuticals Inc ::MOMENTA PHARMACEUTICALS - CO PLANNING FOR GLATOPA 40 MG LAUNCH IN 2H 2018; HOWEVER, POTENTIAL REMAINS FOR 1H 2018 LAUNCH - SEC FILING.  Full Article

Momenta Pharma says Q3 loss per share $0.44
Wednesday, 1 Nov 2017 08:05am EDT 

Nov 1 (Reuters) - Momenta Pharmaceuticals Inc -:Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 revenue $24.1 million versus $29.1 million.Q3 revenue view $30.6 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.44.Q3 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.Momenta Pharmaceuticals - co and Mylan are targeting a first regulatory submission for clinical development of M710 by early 2018​.Momenta Pharmaceuticals - ‍updated non-GAAP operating expense guidance of about $200 million - $210 million for 2017 and $43 million - $53 million for Q4 of 2017​.Momenta Pharmaceuticals Inc - ‍expects to recognize $50 million upfront payment from CSL as revenue in Q4 of 2017​.Momenta Pharmaceuticals Inc - ‍estimates that collaborative reimbursement revenues will be approximately $0 - $2 million in Q4 of 2017​.  Full Article

Momenta And Mylan report initial results from phase 1 clinical trial for M834
Wednesday, 1 Nov 2017 08:00am EDT 

Nov 1 (Reuters) - Momenta Pharmaceuticals Inc :Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept).Mylan NV - ‍M834, a proposed biosimilar of Orencia (Abatacept), did not meet its primary pharmacokinetic (PK) endpoints in phase 1 study​.Mylan NV - ‍Momenta And Co continue to gather and analyze data to inform next steps for M834 program ​.  Full Article

Momenta Pharmaceuticals posts Q2 loss per share $0.50
Wednesday, 2 Aug 2017 08:00am EDT 

Aug 2 (Reuters) - Momenta Pharmaceuticals Inc ::Momenta pharmaceuticals reports second quarter 2017 financial results and provides corporate update.Q2 revenue $23.5 million versus I/B/E/S view $24.6 million.Q2 loss per share $0.50.Q2 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.Momenta pharmaceuticals inc - ‍remain optimistic that co could see a potential glatopa 40 mg approval and launch into marketplace in 2017 timeframe​.Momenta pharmaceuticals inc - ‍updated non-GAAP operating expense guidance of approximately $210 - $230 million for 2017 and $50 - $60 million for Q3​.Momenta pharmaceuticals inc - company continues to expect to recognize revenue from Mylan's $45 million upfront payment on a quarterly basis.Momenta pharmaceuticals inc - also expects to recognize $10 million glatopa 20 mg milestone as revenue in q3 of 2017.Momenta pharmaceuticals inc - also expects to recognize $50 million upfront payment from csl as revenue in q4 of 2017.Momenta pharmaceuticals - at june 30, 2017, co had $456.8 million in cash, cash equivalents and marketable securities compared to $433.7 million at march 31, 2017.  Full Article

Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc
Monday, 24 Jul 2017 06:00am EDT 

July 24 (Reuters) - Amphastar Pharmaceuticals Inc :Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc.Amphastar Pharmaceuticals - ‍jury found claims of Momenta's U.S. patent to be "invalid for lack of enablement and lack of adequate written description"​.  Full Article

Momenta Pharmaceuticals says U.S. court found its patent for manufacturing LOVENOX "was infringed"
Friday, 21 Jul 2017 02:16pm EDT 

July 21 (Reuters) - Momenta Pharmaceuticals Inc ::Momenta Pharmaceuticals announces jury verdict in Enoxaparin Sodium Injection patent litigation against Amphastar.U.S. court issued verdict finding that co's U.S. patent covering methods for manufacturing of generic LOVENOX "was infringed".  Full Article

Amphastar cannot collect $100 mln during Momenta drug patent appeal - judge

A federal judge on Monday ruled that Amphastar Pharmaceuticals Inc must wait to collect a $100 million bond that Momenta Pharmaceuticals Inc and Sandoz Inc posted in a drug patent case it won until after an appellate court hears the dispute.